NIRCO med‎ > ‎drugs‎ > ‎Narkosemittel‎ > ‎Parenterale Anästhetika‎ > ‎

Etomidate

Dosierung/Anwendung (1): iv induction: 0.2-0.5 mg/kg

Warnhinweise und Vorsichtsmassnahmen:
  • Etomidate is associated with a substantially increased risk for 30-day mortality, cardiovascular morbidity, and prolonged hospital stay in patients of ASA class III and IV. Although this study showed only an association between etomidate use and worse patients’ outcomes but not causal relationship, clinicians should use etomidate judiciously, considering that improved hemodynamic stability at induction may be accompanied by substantially worse longer-term outcomes (2).
Referenzen:
  1. Morgan & Mikhail's Clinical Anesthesiology. McGraw-Hill. 2013: p. 183.
  2. Ryu Komatsu et al. Anesthetic Induction with Etomidate, Rather than Propofol, Is Associated with Increased 30-Day Mortality and Cardiovascular Morbidity After Noncardiac Surgery. Anesthesia & Analgesia. 2013;117(6):1329-1337: full text | pdf.